Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4619-4623

  Kobayashi, Masashi ^a   Sonobe, Makoto ^a   Takahashi, Tsuyoshi ^a   Yoshizawa, Akihiko ^b   Ishikawa, Masashi ^a   Kikuchi, Ryutaro ^a   Okubo, Kenichi ^a   Huang, Cheng Long ^a   Date, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adenocarcinoma; BRAF mutation; EGFR; ERBB2 mutation; KRAS; Lung cancer; Squamous cell carcinoma; SSCP; V600E

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CELL PROLIFERATION; CODON; CONTROLLED STUDY; DISTANT METASTASIS; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SMOKING;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CODON; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84855164491     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ueda Y and Fujii Y: Thoracic and cardiovascular surgery in Japan during 2007. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 57(9): 488-513, 2009.
2. Pfister DG, Johnson DH and Azzoli CG: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2): 330-353, 2004. (Pubitemid 41095099)
3. Lynch TJ, Bell DW and Sordella R: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139, 2004. (Pubitemid 38637993)
4. Shepherd FA, Rodrigues Pereira J and Ciuleanu T: National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353(2): 123-132, 2005.
5. Huang C, Yokomise H and Fukushima M: Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol 2(2): 289-229, 2006.
6. Davies H, Bignell GR and Cox C: Mutations of the BRAF gene in human cancer. Nature 417(6892): 949-954, 2002. (Pubitemid 34716871)
7. Brose MS, Volpe P and Feldman M: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62(23): 6997-7000, 2002. (Pubitemid 35424092)
8. Wan PT, Garnett MJ and Roe SM: Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of BRAF. Cell 116(6): 855-867, 2004. (Pubitemid 38410730)
9. Wellbrock C, Ogilvie L and Hedley D: V599EB-RAF is an oncogene in melanocytes. Cancer Res 64(7): 2338-2342, 2004.
10. Hoeflich KP, Gray DC and Eby M: Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66(2): 999-1006, 2006. (Pubitemid 43165968)
11. Hingorani SR and Jacobetz MA: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63(17): 5198-5202, 2003. (Pubitemid 37139827)
12. Gorden A, Osman I and Gai W: Analysis of BRAF and NRAS mutations in metastatic melanoma tissues. Cancer Res 63(14): 3955-395, 2003.
13. Kimura ET and Nikiforova MN: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63(7): 1454-1457, 2003. (Pubitemid 36373628)
14. Yuen ST and Davies H: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62(22): 6451-6455, 2002. (Pubitemid 35364105)
15. Llovet JM, Ricci S and Mazzaferro V: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378-390, 2008.
16. Guevremont C and Jeldres C: Sorafenib in the management of metastatic renal cell carcinoma. Curr Oncol 116: S27-S32, 2009.
17. Tsai J and Lee JT: Discovery of a selective inhibitor of oncogenic B-raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105(8): 3041-3046, 2008. (Pubitemid 351723664)
18. McDermott U and Sharma SV: Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104(50): 19936-19941, 2007.
19. Halilovic E and Solit DB: Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacology 8(4): 419-426, 2008.
20. Sasaki H and Kawano O: Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 133(2): 203-206, 2006.
21. Schmid K and Oehl N: EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15(14): 4554-4560, 2009.
22. Huang C, Liu D and Masuya D: Clinical application of biological markers for treatment of resectable non-small cell lung cancers. Br J Cancer 92(7): 1231-1239, 2005. (Pubitemid 40604397)
23. Sonobe M and Manabe T: Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 93(3): 355-363, 2005. (Pubitemid 43080038)
24. Hatzaki A and Razi E: A modified mutagenic PCR-RFLP method for KRAS codon 12 and 13 mutations detection in NSCLC patients. Mol Cell Probes 15(5): 243-247, 2001. (Pubitemid 33104992)
25. Scagliotti G and Novello S: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer. J Clin Oncol 28(11): 1835-1842, 2010.